<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00383799</url>
  </required_header>
  <id_info>
    <org_study_id>2005-001505-25</org_study_id>
    <nct_id>NCT00383799</nct_id>
  </id_info>
  <brief_title>Iv Amiodarone Versus Iv Procainamide to Treat Haemodynamically Well Tolerated Ventricular Tachycardia</brief_title>
  <official_title>Comparison of Intravenous Amiodarone Versus Intravenous Procainamide for the Acute Treatment of Regular and Haemodynamically Well Tolerated Wide QRS Tachycardia (Probably of Ventricular Origen). The PROCAMIO Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General Universitario Gregorio Marañon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General Universitario Gregorio Marañon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether intravenous amiodarone has less cardiac
      significant adverse events compared to intravenous procainamide in the acute treatment of
      haemodynamically well tolerated wide QRS tachycardia, the majority of them of probably
      ventricular origen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, prospective and randomized study in phase IV. A total of 302 patients will be
      included in the study within 40-50 institutions in Spain. Patients with regular and
      monomorphic tachycardia ≥ 120 bpm, QRS ≥ 120 ms and haemodynamically well tolerated will be
      randomized to receive iv amiodarone (single dosage: 5 mg/kg in 20 minutes) vs iv procainamide
      (single dosage: 10 mg/kg in 20 minutes). The study period will be 40 minutes from infusion
      initiation. Study variables include the presence of clinically cardiac significant adverse
      events: hypotension, syncope, heart failure, symptomatic sinus bradycardia, AV block,
      proarrhythmia and tachycardia acceleration (&lt;20 lpm)and death. Total observation period will
      be 24 hours after the end of the infusion.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Steering Committee decision after inclusion of 74 patients after 6 years and very slow
    inclusion rate
  </why_stopped>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare clinically significant cardiac adverse events occurring within 40 minutes from treatment initiation</measure>
    <time_frame>40 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare efficacy of both therapies in relation to episode termination</measure>
    <time_frame>40 minuutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the rate of total adverse events, cardiac and non cardiac, occurring during an observation period of 24 hours after treatment was applied</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">302</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <condition>Wide QRS Tachycardia</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV procainamide (single dose: 10 mg/kg over 20 min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV Amiodarone (single dose: 5 mg/kg over 20 min)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iv Amiodarone</intervention_name>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iv Procainamide</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with stable tachycardia ≥120 lpm, QRS ≥120 ms and haemodynamically well
             tolerated defined as: 1)Systolic blood pressure ≥90 mmHg, 2) absence of dyspnea at
             rest, 3)absence of peripheric hypoperfusion signs and 4)no severe angina.

          -  Age &gt; 18 years

          -  Written inform consent obtained

        Exclusion Criteria:

          -  Treatment with iv amiodarone or iv procainamide during the previous 24 hours

          -  QRS tachycardia &lt;120 ms

          -  Patients with QRS ≥120 ms tachycardia with haemodynamic compromise that requires
             urgent cardioversion for termination

          -  Irregular tachycardia

          -  Tachycardia that is considered as supraventricular due to physician criteria
             (adenosine and/or vagal manoeuvres response)

          -  Patient that do not want to cooperate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesús Almendral, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario Gregorio Marañón. Madrid. Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando Arribas, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital General Universitario 12 de Octubre. Madrid. Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael Peinado, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital General Universitario La Paz. Madrid. Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfonso Martín, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital de Móstoles. Madrid. Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen del Arco, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital de la Princesa. Madrid. Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dolores Vigil, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital general Universitario Gregorio Marañón. Madrid. Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mercedes Ortiz, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital General Universitario Gregorio Marañón. Madrid. Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Blanca Coll-Vinent, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clinic. Barcelona. Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital El Escorial</name>
      <address>
        <city>El Escorial</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe</name>
      <address>
        <city>Getafe</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa María del Rosell</name>
      <address>
        <city>Cartagena</city>
        <state>Murcia</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Hospitalaria de Cieza</name>
      <address>
        <city>Cieza</city>
        <state>Murcia</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Los Arcos</name>
      <address>
        <city>San Javier</city>
        <state>Murcia</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Basurto</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Cecilio</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Móstoles</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Son Dureta</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Son Llatzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Donostia</name>
      <address>
        <city>San Sebastián</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Valme</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Clínico Universitario</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Río Hortega</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: advanced cardiovascular life support: section 5: pharmacology I: agents for arrhythmias. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation. 2000 Aug 22;102(8 Suppl):I112-28.</citation>
    <PMID>10966669</PMID>
  </reference>
  <reference>
    <citation>ECC Committee, Subcommittees and Task Forces of the American Heart Association. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2005 Dec 13;112(24 Suppl):IV1-203. Epub 2005 Nov 28.</citation>
    <PMID>16314375</PMID>
  </reference>
  <reference>
    <citation>Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA, Roden DM, Silka MJ, Tracy C, Smith SC Jr, Jacobs AK, Adams CD, Antman EM, Anderson JL, Hunt SA, Halperin JL, Nishimura R, Ornato JP, Page RL, Riegel B, Blanc JJ, Budaj A, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL; American College of Cardiology/American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006 Sep 5;114(10):e385-484. Epub 2006 Aug 25.</citation>
    <PMID>16935995</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2006</study_first_submitted>
  <study_first_submitted_qc>October 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2006</study_first_posted>
  <last_update_submitted>April 4, 2016</last_update_submitted>
  <last_update_submitted_qc>April 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ventricular tachycardia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
    <mesh_term>Procainamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

